Clinical Trial

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Study acronym: GABRINOX-ART
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in patients with locally advanced pancreatic adenocarcinoma. The study will also demonstrate the feasibility of combining this intensified chemotherapy with MRI-guided stereotactic radiotherapy in non-progressive patients after the chemotherapy by Gabrinox regimen.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-09-29; most recent amendment 2025-11-28.
Status change: Not Yet Recruiting → Recruiting 2020-12-30
Trial Details
NCT Number NCT04570943
Lead Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Conditions Locally Advanced Pancreatic Adenocarcinoma
Enrollment 103 participants
Start Date 2021-06-16
Primary Completion 2028-01 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-05